SOHO Highlights: State of the Art and Next Questions
CML State of the Art: Dasatinib/Imatinib Dose Optimization, STAMPi Asciminib Efficacy in CP-CML, Treatment Free Remission, Single Cell Analysis
Login to view comments.
Click here to Login